Medicine
Alogliptin and Pioglitazone 25 mg/30 mg tablet
Alogliptin and Pioglitazone 25 mg/30 mg tablet is a generic prescription medicine for oral use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Keep…
Key facts
- Active ingredient (INN)
- Alogliptin and Pioglitazone
- Brand
- Sold under the generic name
- Strength
- 25 mg/30 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Manufacturer
- Padagis Israel Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Keep container tightly closed and protect from moisture and humidity.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BD09 Alogliptin and Pioglitazone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 April 2016
- Identifiers
- RxCUI 1368410, 1368424, 1368431 +1DailyMed set ID 642b1e90-701e-42f2-bac6-a4918738e2c9NDC 45802-402Application NDA022426
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 45802-402-65 | Padagis Israel Pharmaceuticals | 8 April 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Alogliptin and Pioglitazone 25 mg/30 mg tablet.
Other strengths and forms of Alogliptin and Pioglitazone
Clinical summary
Alogliptin and Pioglitazone is a fixed-dose combination of a dipeptidyl peptidase 4 inhibitor, a peroxisome proliferator receptor alpha agonist and a peroxisome proliferator receptor gamma agonist. It is available as tablets for oral use. MedsAcross supplies Alogliptin and Pioglitazone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Alogliptin and PioglitazoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Alogliptin and Pioglitazone prescribing information (Padagis Israel Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Incresync: European public assessment report (EPAR) · European Medicines Agency
Need Alogliptin and Pioglitazone 25 mg/30 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.